Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Long-Term Extension in IPF
NCT01170065Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2010
- Primary completion
- Sep 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 21
01
Overview
A Phase 2 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Jun 2010; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01170065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01170065.